NCT03412565 2025-04-29A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment RegimensJanssen Research & Development, LLCPhase 2 Completed265 enrolled 21 charts 3 FDA